Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Not yet recruiting	Phase 2	2026-04-07		NCT07514429

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Boryung Pharmaceutical Co., Ltd	32
Hanyang University Guri Hospital	7
Ju Hyun Shim	2
National Cancer Center, Korea	52
Samsung Medical Center	207
Seoul National University Bundang Hospital	114
Seoul National University Hospital	277

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	338